25B-NBOH is the microgram-potency descendant of 2C-B, carrying the visual warmth and recreational accessibility of its parent compound into the N-benzyl phenethylamine framework. Structurally, it is 2C-B with an N-(2-hydroxybenzyl) group attached to the terminal nitrogen -- a modification that increases 5-HT2A receptor binding affinity by roughly 10-15 fold over the parent compound and drops the active dose range from the 15-25 mg territory of 2C-B down to approximately 250-750 µg. That potency shift is the defining fact about 25B-NBOH: it moves a well-loved psychedelic into a dosing regime where blotter paper becomes practical and small measurement errors become consequential.
The compound emerged from the same systematic structure-activity research that produced the entire NBOH class -- Martin Hansen's 2014 work at the University of Copenhagen, which mapped 48 N-benzylphenethylamine variants across the 5-HT2A and 5-HT2C receptor landscape. The NBOH modification (2-hydroxybenzyl on nitrogen, as opposed to the 2-methoxybenzyl of the NBOMe series) was the laboratory's key innovation: it retained the dramatic potency enhancement of the NBOMe pharmacophore while introducing a hydrogen bond donor that interacts differently with the 5-HT2A binding pocket. Whether this structural difference is responsible for the apparently lower acute toxicity of NBOH compounds compared to NBOMe compounds remains an open question, but the pattern is consistent enough across the series that it is not mere coincidence.
In practice, 25B-NBOH delivers what users of 2C-B would recognize: vivid, colorful, pattern-rich visuals with a headspace that stays lucid and emotionally warm rather than plunging into the cognitive depths of tryptamine psychedelics. The body load is present but manageable -- vasoconstriction, mild stimulation, some jaw tension -- and reports consistently describe it as lighter than what NBOMe compounds inflict. Duration runs 5-7 hours, substantially shorter than LSD and closer to the 2C-B timeframe. For the research chemical psychedelic community, 25B-NBOH occupies a specific niche: it is the NBOH analog most likely to be taken recreationally rather than for introspective exploration, inheriting 2C-B's reputation as the phenethylamine psychedelic you can actually enjoy at a party without spending six hours questioning the nature of selfhood.
No confirmed fatalities from 25B-NBOH alone have been documented, which is a meaningful distinction from 25B-NBOMe. But the compound is active at doses measured in hundreds of micrograms on unverified blotter paper, vasoconstriction is pharmacologically guaranteed, the dose-response curve is steep, and the human safety dataset is small. The same harm reduction principles that apply to NBOMe compounds -- reagent testing, accurate dosing, never redosing, avoiding stimulant combinations -- are not optional with NBOH compounds. They are the minimum standard for engaging with any substance where the difference between a pleasant evening and a hospital visit can be measured in fractions of a milligram.
Safety at a Glance
High Risk- Reagent Test Your Blotter
- B-NBOH blotters are visually indistinguishable from LSD, NBOMe, and other blotter-active compounds. Reagent testing i...
- Toxicity: Fatality Data No confirmed human fatalities attributed solely to 25B-NBOH have been reported in the scientific or for...
- Overdose risk: Recognizing When Things Have Gone Wrong 25B-NBOH has a better acute safety profile than NBOMe com...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 5 hrs – 10 hrsHow It Feels
The first sign is a subtle electrical prickling across the scalp and forehead, arriving fifteen to twenty minutes after the blotter goes under the tongue. There is a metallic awareness in the sinuses from the sublingual absorption, and the mouth carries a persistent bitter chemical taste -- less caustic than NBOMe but clearly not nothing. A faint stimulant push begins building in the chest. The heart rate climbs modestly. A restless warmth settles into the hands and legs. Colors in the peripheral vision start to intensify, as though someone is reaching behind the world and turning up the saturation dial with careful, deliberate hands.
Within forty-five minutes the visual field undergoes its transformation. Surfaces erupt with intricate geometric overlays -- tight, angular lattices and neon-bright tessellations that tile across walls, skin, and sky with a mechanical precision characteristic of the N-benzyl phenethylamines. Everything shimmers at high frequency. Colors acquire an almost fluorescent quality, as though lit from behind by blacklight. But there is a warmth to the palette that distinguishes 25B-NBOH from its more clinical cousins -- the 2C-B lineage shows through in amber and rose-gold tones threading through the geometry, in the way patterns seem to pulse with a biological rhythm rather than pure mathematical regularity. The body carries a stimulant edge: jaw tension, elevated heartbeat, warmth in the extremities that occasionally borders on uncomfortable but never crosses into the grinding vasoconstriction of NBOMe.
At the peak, typically reached around ninety minutes in and sustained for another two to three hours, the visual geometry becomes extraordinarily dense and layered. Fractal patterns cascade across every surface. Afterimages trail behind moving objects in vivid streaks of color. Closed-eye visuals are kaleidoscopic and rapid -- crystalline structures folding and unfolding with a relentless, jewel-like beauty. The headspace is the surprise. It stays clear. Thoughts remain lucid and organized, with a distinct euphoric uplift and heightened aesthetic appreciation rather than the cognitive disassembly of high-dose tryptamines. Music acquires an almost physical texture -- you can feel the architecture of a chord progression, sense the spatial arrangement of instruments in a mix. Emotionally, the experience tends toward lightness, wonder, and a buoyant playfulness. This is the 2C-B inheritance: a psychedelic that wants you to enjoy yourself rather than interrogate your existence.
The descent begins three to four hours after onset and moves noticeably faster than the long fade of LSD. Geometric overlays gradually dissolve, leaving enhanced color perception and a soft visual shimmer that makes the world look freshly washed. The stimulant body load eases. Residual jaw tension and a mild headache may linger, but there is a pleasant tiredness settling in rather than the wrung-out depletion of harder compounds. Total duration spans five to seven hours. The afterglow carries a crisp, clean quality -- colors remain slightly heightened, music sounds better than usual, and there is a buoyant mood lift that can persist through the following day. The overall impression is of a visual psychedelic that delivered substantial intensity in a compact, physically manageable package.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(26)
- Abnormal heartbeat— Abnormal heartbeat (arrhythmia) is any deviation from the heart's normal rhythm — including beats th...
- Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
- Body load— A diffuse, heavy physical discomfort involving tension, pressure, and malaise in the torso and limbs...
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Difficulty urinating— Difficulty urinating, also known as urinary retention, is the experience of being unable to easily p...
- Dry mouth— A persistent, uncomfortable reduction in saliva production causing the mouth and throat to feel parc...
- Frequent urination— Increased urinary frequency beyond normal patterns, caused by diuretic effects or bladder irritation...
- Headache— A painful sensation of pressure, throbbing, or aching in the head that can range from a dull backgro...
- Increased blood pressure— Increased blood pressure (hypertension) is an elevation of arterial pressure above the normal 120/80...
- Increased bodily temperature— Increased bodily temperature (hyperthermia) is an elevation of core body temperature above the norma...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Increased libido— A marked enhancement of sexual desire, arousal, and sensitivity to erotic stimuli that can range fro...
- Laughter fits— Spontaneous, uncontrollable, and often prolonged episodes of intense laughter that erupt without any...
- Mouth numbing— Mouth numbing is a localized loss of sensation in the tongue, gums, cheeks, and surrounding oral tis...
- Muscle cramp— Muscle cramps are sudden, involuntary, and often painful contractions of muscles that occur as a sid...
- Muscle tension— Persistent partial contractions or tightening of muscles that produces uncomfortable stiffness, cram...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Perception of bodily lightness— Perception of bodily lightness is the subjective feeling that one's body has become dramatically lig...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
- Restless legs— Restless legs is an uncomfortable neurological effect characterized by an irresistible compulsion to...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Stomach cramp— Stomach cramps are sharp, intermittent pains in the abdominal region that can occur when psychoactiv...
- Temperature regulation disruption— Impaired thermoregulation causing unpredictable fluctuations between feeling hot and cold, with risk...
- Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...
Cognitive & Perceptual Effects
Visual(23)
- After images— A visual phenomenon in which a faint, ghostly imprint of a previously viewed image persists in the v...
- Brightness alteration— Perceived increase or decrease in environmental brightness beyond actual illumination levels, common...
- Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
- Colour replacement— A visual phenomenon in which the colors of objects or the entire visual field are statically replace...
- Colour shifting— The visual experience of colors on objects and surfaces cycling through continuous, fluid transforma...
- Depth perception distortions— Alterations in how the distance of objects within the visual field is perceived, causing layers of s...
- Diffraction— The experience of seeing rainbow-like spectrums of color and prismatic halos embedded within bright ...
- Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
- Frame rate suppression— Perception of visual motion as choppy discrete frames rather than smooth continuous flow, resembling...
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
- Magnification— A visual distortion in which objects appear larger or closer than they actually are, as though one's...
- Pattern recognition enhancement— An increased ability and tendency to perceive meaningful patterns, faces, and images within ambiguou...
- Peripheral vision changes— Alterations in side vision ranging from enhanced peripheral awareness to tunnel vision, with charact...
- Perspective distortions— Distortion of perceived depth, distance, and size of real objects, making things appear closer, furt...
- Perspective hallucination— A hallucinatory phenomenon in which the observer's visual perspective shifts from the normal first-p...
- Recursion— The visual field begins to repeat and nest within itself in a self-similar, fractal-like manner, as ...
- Scenery slicing— The visual field fractures into distinct, cleanly cut sections that slowly drift apart from their or...
- Settings, sceneries, and landscapes— The perceived environment in which hallucinatory experiences take place, ranging from recognizable l...
- Symmetrical texture repetition— Textures appear to mirror and tessellate across surfaces in intricate, self-similar symmetrical patt...
- Tracers— Moving objects leave visible trails of varying length and opacity behind them, similar to long-expos...
- Transformations— Objects and scenery undergo perceived visual metamorphosis, smoothly shapeshifting into other recogn...
- Visual acuity enhancement— Vision becomes sharper and more defined than normal, as though a slightly blurry lens has been broug...
Cognitive(18)
- Amnesia— A complete or partial inability to form new memories or recall existing ones during and after substa...
- Analysis enhancement— A perceived improvement in one's ability to logically deconstruct concepts, recognize patterns, and ...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Confusion— An impairment of abstract thinking marked by a persistent inability to grasp or comprehend concepts ...
- Feelings of impending doom— Feelings of impending doom is the sudden onset of an overwhelming, visceral certainty that something...
- Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
- Increased sense of humor— A general amplification of one's sensitivity to finding things humorous and amusing, often causing p...
- Introspection— An enhanced state of self-reflective awareness in which one feels drawn to examine their own thought...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Novelty enhancement— A feeling of increased fascination, awe, and childlike wonder attributed to everyday concepts, objec...
- Paranoia— Irrational suspicion and belief that others are watching, plotting against, or intending harm toward...
- Personal bias suppression— A decrease in the personal, cultural, and cognitive biases through which one normally filters their ...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
- Thought loops— Becoming trapped in a repeating cycle of thoughts, actions, and emotions that loops every few second...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Auditory(4)
- Auditory distortion— Auditory distortion is the experience of sounds becoming warped, pitch-shifted, flanged, or otherwis...
- Auditory enhancement— Auditory enhancement is a heightened sensitivity and appreciation of sound in which music, voices, a...
- Auditory hallucination— Auditory hallucination is the perception of sounds that have no external source — hearing music, voi...
- Auditory misinterpretation— Auditory misinterpretation is the brief, spontaneous misidentification of real sounds as entirely di...
Multi-sensory(6)
- Dosage independent intensity— Dosage independent intensity is the uncommon and poorly understood phenomenon in which a person expe...
- Gustatory hallucination— Gustatory hallucinations are phantom taste experiences in which distinct flavors manifest in the mou...
- Machinescapes— Machinescapes are complex multisensory hallucinations involving the perception of enormous mechanica...
- Scenarios and plots— Scenarios and plots are the narrative structures that emerge within hallucinatory states — coherent ...
- Sensory overload— An overwhelming flood of sensory information that exceeds the brain's ability to process, creating a...
- Synaesthesia— Stimulation of one sense triggers involuntary experiences in another — seeing sounds as colors, tast...
Transpersonal(3)
- Ego death— A profound dissolution of the sense of self in which personal identity, memories, and the boundary b...
- Existential self-realization— A sudden, visceral realization of the profound significance and improbability of one's own existence...
- Unity and interconnectedness— A profound sense that identity extends beyond the self to encompass other people, nature, or all of ...
Pharmacology
Mechanism of Action
25B-NBOH acts as a potent agonist at the serotonin 5-HT2A receptor, the primary target through which all classical psychedelics produce their characteristic effects. The parent compound 2C-B (4-bromo-2,5-dimethoxyphenethylamine) has moderate 5-HT2A affinity. The N-(2-hydroxybenzyl) modification extends the molecule into an auxiliary hydrophobic pocket in the receptor's binding site, increasing affinity approximately 10-15 fold. This is the same principle underlying the NBOMe series, but with a hydroxyl group (-OH) replacing the methoxy group (-OCH3) on the 2-position of the N-benzyl ring -- a substitution that introduces a hydrogen bond donor and produces subtly different receptor interactions.
Receptor Binding and Selectivity
25B-NBOH shows high selectivity for serotonin 5-HT2A and 5-HT2C receptors over other receptor systems. In binding studies, its selectivity for 5-HT2A relative to 5-HT2C, dopamine, adrenergic, and histamine receptors is notably higher than that of many other psychedelics, including LSD. This sharp serotonergic selectivity means the psychoactive profile is dominated by 5-HT2A-mediated effects -- visual distortion, pattern recognition enhancement, altered emotional processing -- without the dopaminergic stimulation of LSD or the broad receptor promiscuity of mescaline.
5-HT2A Activation and Psychedelic Effects
Activation of cortical 5-HT2A receptors, particularly in layer V pyramidal neurons of the prefrontal cortex, disrupts predictive coding -- the brain's top-down filtering system that normally decides what sensory information reaches conscious awareness. The result is a perceptual opening: enhanced pattern recognition, color intensification, geometric visual overlay, and the sense that the world contains more information than your sober brain was allowing through. 25B-NBOH achieves this activation at microgram doses because the N-hydroxybenzyl group positions the molecule optimally within the 5-HT2A binding pocket, an interaction that has been structurally characterized at atomic resolution in crystallographic studies of the related compound 25CN-NBOH.
Route Dependency
25B-NBOH is essentially inactive when swallowed. Rapid first-pass hepatic metabolism destroys the active compound before it reaches systemic circulation at psychoactive concentrations. The only effective administration routes are sublingual and buccal -- holding the blotter against the oral mucosa for 15-20 minutes while the compound absorbs directly into the bloodstream, bypassing the liver. This is a critical pharmacological fact for both identification and harm reduction: a blotter that only works when swallowed is not NBOH.
Pharmacokinetics
Controlled human pharmacokinetic data for 25B-NBOH do not exist. Community reports and structural analog extrapolation suggest onset in 20-45 minutes via sublingual administration, peak effects at 1.5-3 hours, and total duration of 5-7 hours. The compound is lipophilic with efficient blood-brain barrier penetration. Hepatic metabolism likely proceeds through CYP450-mediated hydroxylation and O-demethylation.
Tolerance
Rapid functional tolerance develops within 24-48 hours following a single dose, consistent with all 5-HT2A agonist psychedelics. Cross-tolerance with LSD, psilocybin, mescaline, 2C-B, and other serotonergic psychedelics is complete. A minimum interval of 5-7 days between uses is necessary for baseline sensitivity to return.
Detection Methods
Urine Detection
25B-NBOH is not targeted by standard immunoassay-based urine drug screens. However, due to its phenethylamine backbone, there is a theoretical possibility of cross-reactivity with amphetamine immunoassays, though this has not been consistently reported in clinical literature. Specialized LC-MS/MS methods developed for novel psychoactive substances can detect NBOH compounds and their metabolites in urine for approximately 24 to 48 hours after ingestion, depending on dose and individual metabolism.
Blood and Serum Detection
Blood detection windows for 25B-NBOH are relatively short. Peak plasma concentrations occur within 30 minutes to 2 hours depending on the route of administration (sublingual absorption is typical for NBOH compounds). Blood concentrations fall below detectable thresholds within 6 to 16 hours for most methods. LC-MS/MS remains the only reliable analytical approach for serum detection, as the doses involved (typically hundreds of micrograms to low milligrams) produce low absolute concentrations.
Standard Drug Panel Inclusion
25B-NBOH is NOT included on standard 5-panel, 10-panel, or 12-panel drug screens. It is not specifically targeted by any routine workplace or clinical immunoassay. While some structural similarity to amphetamines exists, cross-reactivity on amphetamine panels is inconsistent and cannot be relied upon for either detection or exclusion. Identification requires specific testing at a reference laboratory equipped for novel psychoactive substance analysis.
Confirmatory Methods
Definitive identification of 25B-NBOH requires LC-MS/MS or high-resolution mass spectrometry (HRMS). GC-MS can also be employed but may require derivatization due to the thermal lability of NBOH compounds. Reference standards are necessary for quantitative confirmation. Forensic and clinical toxicology laboratories that maintain novel psychoactive substance panels are the only facilities reliably capable of this analysis.
Reagent Testing (Harm Reduction)
Reagent testing is critically important for NBOH compounds due to their significantly higher toxicity profile compared to classical psychedelics. The Ehrlich reagent shows NO reaction with 25B-NBOH, which is the single most important distinguishing test: any substance sold as a psychedelic that fails to turn purple with Ehrlich may be an NBOH compound rather than LSD or a tryptamine. The Marquis reagent produces variable results depending on the specific NBOH compound, ranging from no reaction to green or brown color changes. The Mecke reagent may produce a brown or dark green reaction. For harm reduction purposes, always testing with Ehrlich first is essential. The absence of a purple Ehrlich reaction is a strong warning sign that the substance is not a lysergamide or tryptamine and may be a potentially dangerous NBOH compound.
Interactions
| Substance | Status | Note |
|---|---|---|
| 3-FMA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 4-MMC | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 8-Chlorotheophylline | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Adrafinil | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Anandamide | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
| Cannabis | Uncertain | — |
| 1,3-Butanediol | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 25E-NBOH | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T-2 | Low Risk & Synergy | Cross-tolerance exists; effects compound |
History
Origin in Structure-Activity Research (2010-2014)
25B-NBOH was first synthesized as part of the systematic investigation of N-benzylphenethylamine structure-activity relationships conducted by Martin Hansen and colleagues at the University of Copenhagen, with contributions from Torsten Brammer and others who pioneered the NBOH modification around 2010-2012. The research program aimed to develop highly selective 5-HT2A receptor ligands for use as pharmacological tools in neuroscience research. The NBOH modification -- replacing the 2-methoxy group on the N-benzyl ring with a 2-hydroxyl group -- was found to retain the dramatic potency enhancement over parent 2C-x compounds that characterized the NBOMe series while offering different receptor interaction geometry.
Hansen's landmark 2014 paper in ACS Chemical Neuroscience reported the synthesis and characterization of 48 N-benzylphenethylamine variants. 25B-NBOH was among these, contributing binding and functional data to the comprehensive map that ultimately identified 25CN-NBOH as the optimal research tool in the series. The 4-bromo substitution (from the 2C-B scaffold) provided a specific combination of binding affinity and selectivity that was valuable for understanding how halogen substituents on the phenethylamine ring influence receptor pharmacology.
Research Applications
While 25CN-NBOH became the most widely adopted NBOH research tool -- used in PET imaging, receptor crystallography, and signaling bias studies -- the broader NBOH series including 25B-NBOH contributed to the foundational understanding of how N-benzyl modifications interact with the 5-HT2A receptor. The crystallographic structure of 25CN-NBOH bound to 5-HT2A, published by Kim et al. in Cell in 2020, provided atomic-level insight into the binding mode shared by all NBOH compounds.
Appearance on Research Chemical Markets (Mid-2010s)
25B-NBOH appeared on research chemical vendor sites and in forensic drug seizures beginning in the mid-2010s, as NBOH compounds were marketed as alternatives to NBOMe compounds facing escalating legal restrictions worldwide. Sold primarily on blotter paper, 25B-NBOH gained a modest following in the research chemical community for its 2C-B-like visual character and relatively manageable body load. Forensic identifications have been reported in Brazil and Europe, though at substantially lower prevalence than NBOMe compounds.
Legal Status
25B-NBOH occupies a legal gray area in most jurisdictions. In the United States, it is not specifically listed under the Controlled Substances Act, but could be prosecuted under the Federal Analogue Act of 1986 due to its structural and pharmacological similarity to scheduled phenethylamines. In the United Kingdom, it is Class A under the N-benzylphenethylamine catch-all clause. Germany controls it under the NpSG (New Psychoactive Substances Act) since November 2016. Sweden scheduled it in August 2015. Switzerland controls it as a derivative of N-benzylphenethylamine under Verzeichnis E. Legal status varies internationally and continues to evolve.
Harm Reduction
Reagent Test Your Blotter
25B-NBOH blotters are visually indistinguishable from LSD, NBOMe, and other blotter-active compounds. Reagent testing is the only practical field method for differentiation:
- Ehrlich reagent: LSD and other indole compounds turn purple. 25B-NBOH produces no color change. A negative Ehrlich result means the substance is not LSD
- Marquis reagent: Phenethylamine-class compounds produce characteristic reactions distinct from LSD, helping confirm the compound family
- For definitive identification of the exact compound and dose, mass spectrometry or HPLC testing through harm reduction services (DanceSafe, Energy Control, The Loop) is the only reliable method
Sublingual Administration Required
25B-NBOH is inactive when swallowed. Place the blotter under the tongue or against the inner cheek for 15-20 minutes. Do not drink acidic beverages during absorption. After 15-20 minutes, the active compound has been absorbed and the blotter can be removed. If a blotter only produces effects when swallowed, it is not an NBOH compound and you are taking something else.
Start Low, Wait Long
- Threshold: approximately 100-200 µg
- Common: 250-600 µg
- Strong: 600-900 µg
- Blotter potency is unverified. Treat every blotter as unknown and start with a single blotter or a portion thereof
- Onset can take up to 45 minutes. Do not redose during this window. Premature redosing with steep-curve compounds is how manageable experiences become overwhelming ones
Watch Your Circulation
Vasoconstriction is a consistent pharmacological effect. Check warmth and color of fingers, toes, and lips throughout the experience. Maintain a warm environment. Avoid nicotine and caffeine on the same day. If hands or feet become persistently cold, numb, or blue-tinged and do not respond to warming, treat this as a medical warning sign. Do not combine with stimulants or any other vasoconstrictor.
Dangerous Combinations
- Stimulants (amphetamine, cocaine, MDMA) -- compounded vasoconstriction and cardiovascular stress; the single most dangerous category of combination
- Lithium -- seizure risk with all serotonergic psychedelics; absolutely contraindicated regardless of dose
- MAOIs -- serotonin syndrome risk; avoid entirely
- Tramadol -- lowers seizure threshold; contraindicated
- Cannabis -- dramatically amplifies intensity, paranoia, and anxiety; the most common catalyst for difficult experiences with phenethylamine psychedelics
Managing Difficult Experiences
Benzodiazepines (diazepam 5-10 mg, lorazepam 1-2 mg) are the appropriate pharmacological intervention for acute panic or overwhelming intensity. They reliably reduce psychedelic effects without producing dangerous interactions. Change the physical environment: different room, different music, step outside into fresh air. A calm, sober companion providing simple reassurance is the single most effective measure. Call emergency services immediately if seizures, chest pain, severe vasoconstriction, or loss of consciousness occur.
Toxicity & Safety
Fatality Data
No confirmed human fatalities attributed solely to 25B-NBOH have been reported in the scientific or forensic literature. This is a clinically meaningful distinction from 25B-NBOMe, which has been associated with fatalities. However, the absence of documented deaths does not establish safety. It reflects two converging factors: the NBOH class appears to carry lower acute toxicity than the NBOMe class (possibly related to the hydroxyl-vs-methoxy structural difference and its effect on peripheral receptor activation), and NBOH compounds have far lower market prevalence, meaning the total number of human exposures is substantially smaller. Statistical confidence requires sample size, and the sample size is small.
Vasoconstriction
Peripheral vasoconstriction is the most consistent and clinically relevant adverse effect. All N-benzylphenethylamine psychedelics produce vasoconstriction through 5-HT2A and alpha-adrenergic receptor activation on vascular smooth muscle. With 25B-NBOH, this manifests as cold, pale, or numb extremities (especially fingers and toes), elevated blood pressure, and in some cases a tight or constricted sensation in the chest. Community reports consistently describe the vasoconstriction from NBOH compounds as milder than from NBOMe compounds, but it remains a pharmacological certainty and a real clinical concern. Risk is elevated by concurrent use of stimulants, nicotine, caffeine, or other vasoconstrictors, and in individuals with pre-existing cardiovascular conditions, hypertension, or Raynaud's phenomenon.
Cardiovascular Effects
Tachycardia and blood pressure elevation are expected pharmacological effects. At moderate doses in healthy adults, these are generally tolerable. At high doses, in combination with stimulants, or in individuals with cardiac conditions, they represent genuine risk. The cardiovascular burden is additive with other serotonergic or sympathomimetic compounds.
Seizure Risk
Seizures are a documented complication of NBOMe compounds at high doses. While no seizures specifically attributed to 25B-NBOH have been published, the shared receptor pharmacology and the steep dose-response curve make this a plausible risk, particularly at high doses, in combination with seizure-threshold-lowering drugs (lithium, tramadol), or in individuals with pre-existing seizure disorders.
Psychological Risks
The relatively clear and lucid headspace of 25B-NBOH at moderate doses can become disorienting and anxiogenic at higher doses. Acute panic, thought loops, paranoia, and perceptual overwhelm are reported adverse effects. The visual intensity can exceed what users expect from a blotter-format psychedelic, and the gap between "enjoyable" and "overwhelming" may be smaller than anticipated. Pre-existing vulnerability to anxiety or psychotic disorders increases risk.
Drug Interactions
- Stimulants and vasoconstrictors -- strongly contraindicated; compounding vasoconstriction with potential for cardiovascular crisis
- Lithium -- absolutely contraindicated; documented seizure risk with all serotonergic psychedelics
- MAOIs -- serotonin syndrome risk; avoid
- Tramadol -- seizure threshold reduction; contraindicated
- Cannabis -- unpredictable amplification of intensity and psychological adverse effects
- Other psychedelics -- additive effects; avoid stacking
Contraindications
Cardiovascular disease, hypertension, vascular disorders including Raynaud's phenomenon, personal or family history of psychotic disorders (schizophrenia, schizoaffective disorder, bipolar I), seizure disorders, and concurrent use of lithium, MAOIs, stimulants, or tramadol.
Addiction Potential
25B-NBOH is not addictive. It produces no physical dependence, no withdrawal syndrome, and the serotonergic psychedelic mechanism provides no pharmacological basis for compulsive redosing. Rapid tolerance develops within 24-48 hours of a single dose, making consecutive daily use self-defeating as effects diminish sharply with each repetition. Full cross-tolerance exists with LSD, psilocybin, mescaline, 2C-B, and all other 5-HT2A-mediated psychedelics, preventing substitution patterns. Baseline sensitivity returns within approximately 5-7 days, which naturally spaces out any pattern of use. The experience itself, while more recreational and lighter-bodied than many psychedelics, still demands enough mental and physical energy that most users have no desire to repeat it the following day. Serotonergic psychedelics as a class rank lowest on every major addiction liability scale. A small number of psychedelic users develop patterns of psychological reliance on repeated psychedelic experiences, but this is a behavioral pattern not driven by the pharmacology of any specific compound, and it is uncommon.
Overdose Information
Recognizing When Things Have Gone Wrong
25B-NBOH has a better acute safety profile than NBOMe compounds, but microgram-active substances with steep dose-response curves can produce dangerous effects, particularly at high doses, in combination with other drugs, or in vulnerable individuals. The distinction between a difficult but manageable experience and a medical emergency is defined by the presence of physiological danger signs.
Call Emergency Services Immediately For
- Seizures or rhythmic, uncontrollable muscle jerking
- Severe vasoconstriction: extremities that are cold, blue, numb, and not improving with warming
- Chest pain or significant difficulty breathing
- Body temperature that feels dangerously elevated (hot skin, profuse sweating or paradoxical dry skin)
- Loss of consciousness or complete unresponsiveness
- Extreme agitation with inability to communicate or respond to surroundings
These are not symptoms that will "pass on their own." They require medical assessment.
Psychological Overwhelm vs. Medical Emergency
Most difficult 25B-NBOH experiences are psychological rather than physiological: overwhelming visual intensity, thought loops, acute anxiety, a sense that the experience will never end. These are genuinely distressing but not life-threatening.
For psychological crisis:
- Change the environment immediately -- different room, different lighting, different music, step outside
- Provide calm, steady physical presence; do not crowd the person or speak rapidly
- Simple, repeated reassurance: "You took a substance. This is temporary. You are safe. It will end."
- Benzodiazepines (diazepam 5-10 mg, lorazepam 1-2 mg) reliably reduce psychedelic intensity and anxiety without dangerous interaction
- Do not use antipsychotics as a first-line intervention
Hospital Management
There is no specific antidote for NBOH toxicity. Treatment is supportive:
- Seizures: IV benzodiazepines first-line (diazepam, midazolam, lorazepam); barbiturates or propofol for refractory cases
- Vasoconstriction: Warm environment, IV fluids, monitoring; vasodilators (nitroprusside, phentolamine) if perfusion is compromised
- Cardiovascular instability: IV fluids for hypotension; short-acting antihypertensives for dangerous blood pressure elevation; beta-blockers avoided due to unopposed alpha-adrenergic vasoconstriction risk
- Hyperthermia: Active external cooling; antipyretics are ineffective as the mechanism is not prostaglandin-mediated
- Agitation: High-dose benzodiazepines; physical restraint minimized to reduce rhabdomyolysis risk
Prevention
Conservative dosing, never redosing during the onset window, avoiding all dangerous combinations, and the presence of a sober companion who knows what was taken and can call for help are the most effective overdose prevention measures. Tell paramedics exactly what was taken. Good Samaritan laws in most jurisdictions protect people who call emergency services during drug-related emergencies.
Tolerance
| Full | almost immediately after ingestion |
| Half | 1 week |
| Zero | 2 weeks |
Cross-tolerances
Legal Status
Brazil: As of December 10, 2018, 25B-NBOH has been added to Portaria SVS/MS nº 344. Possession, distribution and use of this substance is now considered illegal.
Germany: 25B-NBOH is controlled under the NpSG (New Psychoactive Substances Act) as of November 26, 2016. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Sweden: The Riksdag added 25B-NBOH to Narcotic Drugs Punishments Act under swedish schedule I ("substances, plant materials and fungi which normally do not have medical use") as of August 18, 2015, published by Medical Products Agency (MPA) in regulation HSLF-FS 2015:12
Switzerland: 25B-NBOH can be considered a controlled substance as a defined derivative of N-Benzylphenethylamine under Verzeichnis E point 131. It is legal when used for scientific or industrial use.
United Kingdom: 25B-NBOH is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause.
United States: 25B-NBOH is not a controlled substance in the United States but possession or distribution for human use could potentially be prosecuted under the Federal Analogue Act due to its structural and pharmacological similarities to 25B-NBOMe.
Responsible use
Research chemical
Hallucinogen
Phenethylamine
25B-NBOMe
25B-NBOH (Wikipedia)
25B-NBOH (Isomer Design)
Experience Reports (2)
Tips (7)
Clear your schedule for the full duration of 25B-NBOH plus afterglow. Do not plan any obligations, driving, or important decisions for the day. Having a time pressure or commitment hanging over you adds unnecessary anxiety.
Start with a low dose of 25B-NBOH if it is your first time. You can always take more next time but you cannot take less once ingested. The difference between a comfortable and an overwhelming experience can be surprisingly small.
Always test 25B-NBOH with an Ehrlich reagent before use. A positive reaction (purple/pink color change) confirms the presence of an indole/lysergamide compound. No reaction could indicate a dangerous substitute like an NBOMe.
Do not combine 25B-NBOH with other psychedelics, stimulants, or serotonergic substances. The NBOx compounds have a higher risk profile than classical psychedelics, and combinations significantly increase the danger of adverse cardiovascular events.
25B-NBOH is extremely potent and should never be insufflated. The margin between an active dose and a dangerous dose is narrow. Always use volumetric dosing and start very low.
People with a personal or family history of psychotic disorders (schizophrenia, bipolar type I) should avoid 25B-NBOH and other psychedelics. These substances can trigger or exacerbate psychotic episodes in predisposed individuals.
Community Discussions (1)
See Also
Similar by Effects
Same Class
References (4)
- Psilocybin produces substantial and sustained decreases in depression and anxiety — Griffiths et al. Journal of Psychopharmacology (2016)paper
- Neural correlates of the LSD experience revealed by multimodal neuroimaging — Carhart-Harris et al. PNAS (2016)paper
- 25B-NBOH - TripSit Factsheet
TripSit factsheet for 25B-NBOH
tripsit - 25B-NBOH - Wikipedia
Wikipedia article on 25B-NBOH
wikipedia